This randomized, placebo-controlled, double-blind (included open arm of KRN1493
(cinacalcet)), parallel-group, multi-center study is designed to evaluate efficacy and safety
in cohorts comprising KHK7580, its placebo and KRN1493 (cinacalcet) orally administered for
three weeks for secondary hyperparathyroidism patients receiving hemodialysis.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.